R&D

In gastroenterology, abdominal pain, cramping, bloating, constipation, diarrhea are all very common clinical symptoms that generate more than 170 million physician visits annually in the EU and in the US. Usually, patients suffering from these symptoms consult at the primary care, and are then referred to specialists depending on the initial diagnosis. Augurix aims at providing physicians easy-to-use diagnostic tools to discriminate and stratify patients to offer them a tailored therapeutic solution.

Discrimination – need at the primary care: The first concern for physicians at the primary care is to be able to discriminate patients with a benign functional gastrointestinal disorder, typically Irritable Bowel Disease (IBS) from those suffering from an organic disorder, either with inflammatory background (Crohn’s Disease or Ulcerative Colitis, together covered by the umbrella term Inflammatory Bowel Disease – IBD), autoimmune background (Celiac Disease), infectious background (whether bacterial or viral) or oncology background. We address this need by developing in-vitro diagnostic test devices specifically designed to screen-out diseases with a very high accuracy.

Stratification – need at the specialist’s site: Heading a step forward, once the origin of the disease has been established, some conditions require a stratification of the patients in different groups, in order to propose the most suitable and personalized therapeutic approach. In IBD, such stratification is required to identify patients suffering from the non-evolutive form – treated with corticosteroids, aminosalicylates, and immunosuppressive therapies – from patient suffering from the chronic fibrotic form – treated with biological therapies (anti-TNF). We address this need by partnering with academia in the development of new specific biomarkers.

Augurix Pipeline